Sanofi says Gaucher pill studies meet goals

PARIS Fri Feb 15, 2013 10:44pm IST

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013. REUTERS/Jacky Naegelen

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company's 2012 annual results presentation in Paris February 7, 2013.

Credit: Reuters/Jacky Naegelen

Related Topics


Coal Mining In The Punjab

Coal Mining In The Punjab

In Choa Saidan Shah miners dig coal with crude pick axes and load it onto donkeys to be transported to the surface earning a team of 4 workers around $10 to be split between them.  Slideshow 

PARIS (Reuters) - Sanofi said its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.

Eliglustat tartrate could become the first oral treatment for Gaucher disease - a rare genetic disorder affecting some 10,000 patients - and shake up the market for therapies that currently have to be injected bi-weekly.

Eliglustat could generate annual sales of $360 million by 2017, according to ThomsonReuters Pharma forecasts.

Patients with Gaucher disease are deficient in an enzyme that breaks down a certain type of fat, leading to potentially life-threatening organ damage and bone problems.

The first study, presented at a medical congress on Friday, compared eliglustat with a placebo, while the second compared it with Cerezyme, an injectable treatment also sold by Sanofi.

Patients treated with the pill showed a "statistically significant improvement" in the size of their spleen - which typically swells as a result of Gaucher disease - without reporting serious side effects, Sanofi said.

Eliglustat also proved to be as good as Cerezyme at treating the symptoms of the disease, the drugmaker added.

Full data from the second trial will be presented at a medical meeting in the second half of 2013, Sanofi said in a statement.

A third late-stage study is currently testing whether the dosage for eliglustat could be reduced to once from twice daily.

In addition to Cerezyme, which for many years dominated the Gaucher market and was at one point the most expensive drug in the world, costing more than $200,000 a year, current treatments include Shire's Vpriv and Elelyso, sold by Pfizer.

(Reporting by Elena Berton; Editing by Christian Plumb and James Regan)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Disease Outbreak


Reading the Brain

Reading the Brain

Guilt may spoil restorative effects of entertainment.  Full Article 

Heart Matters

Heart Matters

Weekday heart attacks still getting quicker treatment at hospitals.  Full Article 

Tackling Stress

Tackling Stress

'Interreality' may enhance stress therapies.  Full Article 

Jogging Helps

Jogging Helps

Short jogs linked to lower risk of death from heart disease.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage